MOLUNAMAX 200 Capsule 10’s

MOLUNAMAX 200 contains Molnupiravir which belongs to the group of medicines called Antiviral drugs. It is used in adults to manage mild to moderate COVID-19 disease who are at risk of developing severe illness. COVID-19 is a highly infectious and spreading respiratory disease caused by the SARS-CoV-2 virus. It is characterized by symptoms such as fever, chills, sore throat, cough, shortness of breath, weakness, body aches, headache, loss of taste or smell, runny nose, diarrhoea, nausea, and vomiting. MOLUNAMAX 200 is not recommended for use in patients who are allergic to molnupiravir. It should be used with caution in patients who are scheduled to undergo liver transplant surgery and in patients with chronic liver and kidney disease. [GNKEYWORD] is not recommended for use in pregnant and breastfeeding women. Also, it is not recommended for use in children and adolescents (below 18 years of age) and it should be used caution in elderly patients (aged above 60 years). Consult your doctor before taking this medicine. The common side effects associated with the use of MOLUNAMAX 200 are diarrhoea, nausea, dizziness, and headache. Contact your doctor if any of the symptom worsens. USES OF MOLUNAMAX 200 Manages mild to moderate COVID-19 disease HOW MOLUNAMAX 200 WORKSMOLUNAMAX 200 reduces the risk of developing severe illness in mild to moderate COVID-19 disease, where molnupiravir works by converting into a metabolite that gets incorporated into the genetic material of the new virus that results in impaired ability of the virus to multiply/replicate its own copies leading to reduced viral load in the lungs thus preventing the risk of developing severe illness in the affected individuals. DIRECTIONS FOR USETake MOLUNAMAX 200 as advised by your physician. Swallow the medicine with a glass of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition. SIDE EFFECTS OF MOLUNAMAX 200COMMON diarrhoea nausea dizziness headache UNCOMMON vomiting rash hives (red, itchy skin) HOW TO MANAGE SIDE EFFECTSHeadache: Apply hot or cold-water bag on your head. Try taking rest in a quiet and dark room. Apply pain relieving balm on your forehead if necessary. Consult your doctor if the symptom does not improve. Dizziness: Lie down until dizziness passes and get up slowly. Do not bend down suddenly. Get a lot of rest. Walk slowly and carefully. Take plenty of fluids. Avoid drinking alcohol or smoking cigarettes. Consult your doctor if the symptom does not improve. Diarrhoea: Drink lot of fluids, such as water to keep yourself hydrated. Try to avoid taking any medicine on your own to manage diarrhoea and consult your doctor if the symptom gets worse. Nausea and vomiting: Try to take MOLUNAMAX 200 with or just after a meal or a snack. Stick to simple meals. Avoid eating fried, oily and spicy foods. Consult your doctor if the symptom gets worse. WARNING & PRECAUTIONSPREGNANCYMOLUNAMAX 200 is not recommended for use during pregnancy. Women with childbearing potential should use effective birth control while taking MOLUNAMAX 200. Consult your doctor before taking this medicine. BREASTFEEDINGMOLUNAMAX 200 is not recommended for use in breastfeeding women. Consult your doctor before taking MOLUNAMAX 200. DRIVING AND USING MACHINESConsult your doctor if MOLUNAMAX 200 affects your ability to drive or operative machines. KIDNEYMOLUNAMAX 200 should be used with caution in patients with kidney problems such as chronic kidney disease. Consult your doctor before taking MOLUNAMAX 200. LIVERMOLUNAMAX 200 should be used with caution in patients with chronic liver disease and in patients planned for liver transplant surgery. Consult your doctor before taking MOLUNAMAX 200. ALLERGYDo not take MOLUNAMAX 200 if you are allergic to molnupiravir or any other ingredients of this medicine. Consult your doctor before taking MOLUNAMAX 200. OTHERSUse in Paediatrics: MOLUNAMAX 200 is not recommended for use in children and adolescents (below 18 years of age). Consult child’s doctor for advice. Use in Geriatrics: MOLUNAMAX 200 should be used with caution in elderly patients (aged above 60 years). Consult your doctor before taking MOLUNAMAX 200. INTERACTIONSA. Drug-Drug Interactions: Before taking MOLUNAMAX 200, inform your doctor if you are taking any medicines including prescription or non-prescription medicines and herbals or vitamin supplements. Overdosage: If you or anyone else accidentally takes too much of MOLUNAMAX 200, consult your doctor immediately or visit the nearby hospital if you experience any unusual symptoms. SYNOPSIS Drug : Molnupiravir Pharmacological Category : Antiviral drug Therapeutic Indication : Mild to Moderate COVID-19 Dosage Forms : Capsule MORE INFORMATION Keep the medicine out of reach of children Store MOLUNAMAX 200 at room temperature FAQs ABOUT MOLUNAMAX 200What is MOLUNAMAX 200 used for? MOLUNAMAX 200 is used in adults to manage mild to moderate COVID-19 disease who are at risk of developing severe illness. COVID-19 is a highly infectious and spreading respiratory disease caused by the SARS-CoV-2 virus, generally characterized by symptoms such as fever, chills, sore throat, cough, shortness of breath, and weakness. What happens if you take more MOLUNAMAX 200 than your required dose? If you or anyone else accidentally takes too much of MOLUNAMAX 200, consult your doctor immediately or visit the nearby hospital if you experience any unusual symptoms. What common side effects are seen with MOLUNAMAX 200? The most common side effects associated with the use of MOLUNAMAX 200 are diarrhoea, nausea, dizziness, or headache. Contact your doctor if any of the symptoms worsen. Who should avoid taking MOLUNAMAX 200? MOLUNAMAX 200 is not recommended for use in patients who are allergic to molnupiravir. It is also not recommended for use during pregnancy and in breastfeeding women. This medicine is not recommended for use in children or adolescents (below 18 years of age). Consult your doctor for advice before taking MOLUNAMAX 200. How MOLUNAMAX 200 works? MOLUNAMAX 200 reduces the risk of developing severe illness in mild to moderate COVID-19 disease, where molnupiravir works by converting into a metabolite that gets incorporated into the genetic material of the new virus that results in impaired ability of the virus to multiply/replicate its own copies leading to reduced viral load in the lungs thus preventing the risk of developing severe illness in the affected individuals. What if I forget to take a dose of MOLUNAMAX 200? If you forgot to take MOLUNAMAX 200 dose within 10 hours of the time, take it as early as possible. Do not double the dose to make up for the forgotten one. If you are not sure, then consult your doctor before taking the medicine. When to stop taking MOLUNAMAX 200? Do not stop taking MOLUNAMAX 200 on your own without consulting your doctor since it may increase your chance of getting severely ill from COVID-19 disease. Consult your doctor before taking MOLUNAMAX 200. REFERENCES1. World Health Organization. Molnupiravir. WHO Drug Information. March 2022. Page – 16. 2. Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra. Molnupiravir in COVID-19: A systematic review of literature. NIH National Library of Medicine. National Centre for Biotechnology Information. PMC PubMed Central. October 2021. [Accessed on 1st August 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556684/ 3. Man Fai Law, Rita Ho, Kimmy Wan Tung Law, and Carmen Ka Man Cheung. Gastrointestinal and hepatic side effects of potential management for COVID-19 and vaccination in patients with chronic liver diseases. NIH National Library of Medicine. National Centre for Biotechnology Information. PMC PubMed Central. December 2021. [Accessed on 1st August 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727202/ 4. Angelica Jayk Bernal, Monica M. Gomes da Silva, Dany B. Musungaie, Evgeniy Kovalchuk, Antonio Gonzalez, Virginia Delos Reyes, Alejandro Martín-Quiros, Yoseph Caraco, Angela Williams-Diaz, Michelle L. Brown, Jiejun Du, Alison Pedley, Christopher Assaid, Julie Strizki, Jay A. Grobler, Hala H. Shamsuddin, Robert Tipping, Hong Wan, Amanda Paschke, Joan R. Butterton, Matthew G. Johnson, and Carisa De Anda, the Move-Out Study Group. Molnupiravir for Oral Management of Covid-19 in Non-hospitalized Patients. NIH National Library of Medicine. National Centre for Biotechnology Information. PMC PubMed Central. December 2021. [Accessed on 1st August 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693688/ 5. Merck Sharp & Dohme B.V. Electronic Medicines Compendium (EMC). [Revised in November 2021] [Accessed on 1st August 2022] https://www.medicines.org.uk/emc/files/pil.13044.pdf USEFUL DIAGNOSTIC TESTS RT-PCR Test Antigen Test